Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 23231439)

1.

Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.

Jacobs J, Grum-Tokars V, Zhou Y, Turlington M, Saldanha SA, Chase P, Eggler A, Dawson ES, Baez-Santos YM, Tomar S, Mielech AM, Baker SC, Lindsley CW, Hodder P, Mesecar A, Stauffer SR.

J Med Chem. 2013 Jan 24;56(2):534-46. doi: 10.1021/jm301580n. Epub 2013 Jan 3.

2.

Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding.

Turlington M, Chun A, Tomar S, Eggler A, Grum-Tokars V, Jacobs J, Daniels JS, Dawson E, Saldanha A, Chase P, Baez-Santos YM, Lindsley CW, Hodder P, Mesecar AD, Stauffer SR.

Bioorg Med Chem Lett. 2013 Nov 15;23(22):6172-7. doi: 10.1016/j.bmcl.2013.08.112. Epub 2013 Sep 7.

3.

Discovery of non-covalent inhibitors of the SARS main proteinase 3CLpro.

Jacobs J, Zhou S, Dawson E, Daniels JS, Hodder P, Tokars V, Mesecar A, Lindsley CW, Stauffer SR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Oct 30 [updated 2013 Feb 28].

4.

Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.

Ghosh AK, Xi K, Grum-Tokars V, Xu X, Ratia K, Fu W, Houser KV, Baker SC, Johnson ME, Mesecar AD.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5876-80. Epub 2007 Aug 19.

5.

Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.

Ghosh AK, Takayama J, Aubin Y, Ratia K, Chaudhuri R, Baez Y, Sleeman K, Coughlin M, Nichols DB, Mulhearn DC, Prabhakar BS, Baker SC, Johnson ME, Mesecar AD.

J Med Chem. 2009 Aug 27;52(16):5228-40. doi: 10.1021/jm900611t.

6.

High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.

Blanchard JE, Elowe NH, Huitema C, Fortin PD, Cechetto JD, Eltis LD, Brown ED.

Chem Biol. 2004 Oct;11(10):1445-53.

PMID:
15489171
7.

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.

Thanigaimalai P, Konno S, Yamamoto T, Koiwai Y, Taguchi A, Takayama K, Yakushiji F, Akaji K, Chen SE, Naser-Tavakolian A, Schön A, Freire E, Hayashi Y.

Eur J Med Chem. 2013 Oct;68:372-84. doi: 10.1016/j.ejmech.2013.07.037. Epub 2013 Aug 9.

PMID:
23994330
8.

Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.

Grum-Tokars V, Ratia K, Begaye A, Baker SC, Mesecar AD.

Virus Res. 2008 Apr;133(1):63-73. Epub 2007 Mar 29.

9.

Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.

Ghosh AK, Takayama J, Rao KV, Ratia K, Chaudhuri R, Mulhearn DC, Lee H, Nichols DB, Baliji S, Baker SC, Johnson ME, Mesecar AD.

J Med Chem. 2010 Jul 8;53(13):4968-79. doi: 10.1021/jm1004489.

10.

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Chen L, Gui C, Luo X, Yang Q, Günther S, Scandella E, Drosten C, Bai D, He X, Ludewig B, Chen J, Luo H, Yang Y, Yang Y, Zou J, Thiel V, Chen K, Shen J, Shen X, Jiang H.

J Virol. 2005 Jun;79(11):7095-103.

11.

Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.

Yang Q, Chen L, He X, Gao Z, Shen X, Bai D.

Chem Pharm Bull (Tokyo). 2008 Oct;56(10):1400-5.

12.
13.

Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.

Lu IL, Mahindroo N, Liang PH, Peng YH, Kuo CJ, Tsai KC, Hsieh HP, Chao YS, Wu SY.

J Med Chem. 2006 Aug 24;49(17):5154-61.

PMID:
16913704
14.
15.

Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings.

Lee H, Mittal A, Patel K, Gatuz JL, Truong L, Torres J, Mulhearn DC, Johnson ME.

Bioorg Med Chem. 2014 Jan 1;22(1):167-77. doi: 10.1016/j.bmc.2013.11.041. Epub 2013 Dec 1.

16.

Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.

Liu W, Zhu HM, Niu GJ, Shi EZ, Chen J, Sun B, Chen WQ, Zhou HG, Yang C.

Bioorg Med Chem. 2014 Jan 1;22(1):292-302. doi: 10.1016/j.bmc.2013.11.028. Epub 2013 Nov 21.

PMID:
24316352
17.

Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.

Tsai KC, Chen SY, Liang PH, Lu IL, Mahindroo N, Hsieh HP, Chao YS, Liu L, Liu D, Lien W, Lin TH, Wu SY.

J Med Chem. 2006 Jun 15;49(12):3485-95.

PMID:
16759091
18.

Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.

Shie JJ, Fang JM, Kuo CJ, Kuo TH, Liang PH, Huang HJ, Yang WB, Lin CH, Chen JL, Wu YT, Wong CH.

J Med Chem. 2005 Jun 30;48(13):4469-73.

PMID:
15974598
19.

Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.

Goetz DH, Choe Y, Hansell E, Chen YT, McDowell M, Jonsson CB, Roush WR, McKerrow J, Craik CS.

Biochemistry. 2007 Jul 31;46(30):8744-52. Epub 2007 Jul 3.

PMID:
17605471
20.

A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.

Xiong B, Gui CS, Xu XY, Luo C, Chen J, Luo HB, Chen LL, Li GW, Sun T, Yu CY, Yue LD, Duan WH, Shen JK, Qin L, Shi TL, Li YX, Chen KX, Luo XM, Shen X, Shen JH, Jiang HL.

Acta Pharmacol Sin. 2003 Jun;24(6):497-504.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk